Back to results
TerminatedPhase 3

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

NCT01028586

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Enquire Central Contact

Geneva, Switzerland

View on ClinicalTrials.gov
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) — TrialFind